Characteristics | All patients N = 4985 | No ED visits N = 2212 | At least one ED visit N = 2773 | |
Age (years), mean ± SD | 54 ± 14 | 55 ± 14.1 | 53.7 ± 13.8 | |
Gender, N (%), female | 3081 (61.8%) | 1318 (59.6%) | 1763 (63.6%) | |
Smoking, N (%) | 1228 (24.6%) | 503 (22.7%) | 725 (26.1%) | |
Type of malignancy, N (%) | Proportion from entire population visited ED, n (%) | Proportion from each cancer type, n (%) | ||
Solid | 4421 (88.7%) | 1989 (89.9%) | 2432 (87.7%) | 2432 (55%) |
Breast cancer | 2046 (41%) | 951 (43%) | 1095 (39.5%) | 1095 (53.5%) |
Gastrointestinal cancer | 843 (17%) | 287 (13%) | 556 (20%) | 556 (65.9%) |
Prostate cancer | 324 (6.5%) | 224 (10.1%) | 100 (3.6%) | 100 (30.4%) |
Genitourinary cancer | 233 (4.7%) | 146 (6.6%) | 87 (3.1%) | 87 (37.33%) |
Lung cancer | 287 (5.7%) | 89 (4%) | 198 (7.1%) | 198 (68.9%) |
Others | 688 (13.8%) | 292 (13.2%) | 396 (14.2%) | 396 (57.5%) |
Hematology/N (%) | 564 (11.3%) | 223 (10.1%) | 341 (12.3%) | 341 (60.4%) |
Leukemia | 70 (1.4%) | 17 (0.8%) | 53 (1.9%) | 53 (75.7%) |
Lymphoma | 387 (7.8%) | 166 (7.5%) | 221 (7.9%) | 221 (57.1%) |
Multiple myeloma | 107 (2.1%) | 40 (1.8%) | 67 (2.4%) | 67 (62.6%) |
Chemotherapy cycles received, median (IQR) | 6 (3–11) | 5 (2–10) | 2 (1–3) |